Publication at Faculty of Medicine in Hradec Králové |
2023
Abstract
Immunotherapy has become an integral part of the treatment of metastatic melanoma. Despite the successes achieved by immunotherapy, there is a group of patients in whom anti-PD-1 monotherapy is not effective or it is not possible to administer a combination of anti-PD-1 with anti-CTLA-4.
For these reasons, it is good that research in this area has not stopped. It is currently possible to indicate the treatment with a combination of anti-PD-1 (nivolumab) with anti-LAG-3 (relatlimab) in one intravenous infusion (Opdualag).